{
    "Clinical Trial ID": "NCT00005957",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Standard Breast Irradiation",
        "  radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.",
        "INTERVENTION 2: ",
        "  Breast Radiation Plus Regional Radiation",
        "  regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)",
        "  Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically proven invasive carcinoma of the breast",
        "  No evidence of T4, N2-3, or M1 disease prior to surgery",
        "  Node positive or high-risk node negative",
        "  Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or segmental mastectomy) and axillary node dissection or sentinel node biopsy required and must be a candidate for breast radiotherapy after BCT",
        "  Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision",
        "  Patients with microscopically focally positive margins (defined as no greater than 3 times high power fields) are candidates for breast radiotherapy plus a boost to the lumpectomy site",
        "  Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria",
        "  If node positive, then a level I and II axillary dissection must be performed",
        "  No evidence of residual disease in axilla after dissection",
        "  Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy",
        "  High risk of regional and systemic recurrence due to one of the following:",
        "  Pathologically positive axillary lymph nodes",
        "  Pathologically negative axillary lymph nodes with one of the following:",
        "  Primary tumor greater than 5 cm",
        "  Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:",
        "  Estrogen receptor negative",
        "  Skarf-Bloom-Richardson grade 3",
        "  Lymphovascular invasion",
        "  Hormone receptor status:",
        "  Estrogen and progesterone receptor status known",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "  16 and over",
        "  Sex:",
        "  Female",
        "  Menopausal status:",
        "  Premenopausal or postmenopausal",
        "Performance status:",
        "  ECOG 0-2",
        "  Life expectancy:",
        "  At least 5 years",
        "  Hematopoietic:",
        "  Not specified",
        "  Hepatic:",
        "  SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)*",
        "  Alkaline phosphatase no greater than 3 times ULN* NOTE: * Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations",
        "  Renal:",
        "  No serious nonmalignant renal disease",
        "  Cardiovascular:",
        "  No serious nonmalignant cardiovascular disease",
        "  Pulmonary:",
        "  No serious nonmalignant pulmonary disease",
        "  Other:",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception",
        "  No other serious nonmalignant disease (e.g., systemic lupus erythematosus or scleroderma) that would preclude definitive surgery or radiotherapy",
        "  No other malignancy except:",
        "  Nonmelanomatous skin cancer",
        "  Carcinoma in situ of the cervix or endometrium",
        "  Contralateral noninvasive breast cancer (unless prior radiotherapy to the contralateral breast)",
        "  Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation",
        "  No psychiatric or addictive disorder that would preclude informed consent or study compliance",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  Not specified",
        "  Chemotherapy:",
        "  See Disease Characteristics",
        "  Concurrent standard adjuvant chemotherapy allowed",
        "  Endocrine therapy:",
        "  See Disease Characteristics",
        "  Concurrent standard adjuvant hormonal therapy allowed",
        "  Radiotherapy:",
        "  See Disease Characteristics",
        "  Surgery:",
        "  See Disease Characteristics"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Survival",
        "  Duration of study",
        "  Time frame: 10 years",
        "Results 1: ",
        "  Arm/Group Title: Standard Breast Irradiation",
        "  Arm/Group Description: radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.",
        "  Overall Number of Participants Analyzed: 916",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of alive at 10 years  82        (79 to 84)",
        "Results 2: ",
        "  Arm/Group Title: Breast Radiation Plus Regional Radiation",
        "  Arm/Group Description: regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)",
        "  Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.",
        "  Overall Number of Participants Analyzed: 916",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of alive at 10 years  83        (80 to 85)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/927 (0.11%)",
        "  Secondary Malignancy 1/927 (0.11%)",
        "Adverse Events 2:",
        "  Total: 3/893 (0.34%)",
        "  Secondary Malignancy 3/893 (0.34%)"
    ]
}